GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (LTS:0IJO) » Definitions » Net Interest Income (for Banks)

Exelixis (LTS:0IJO) Net Interest Income (for Banks)


View and export this data going back to 2018. Start your Free Trial

What is Exelixis Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


Exelixis Business Description

Industry
Traded in Other Exchanges
Address
1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.